Introduction
Telomerase, a specialized RNA-directed DNA polymerase that extends telomeres of eukaryotic chromosomes, has been implicated as playing an important role in cell survival. The activity of telomerase is repressed in many human somatic tissues, whereas the enzyme is activated during tumor progression in most human cancers (Blackburn, 1992; de Lange, 1994 de Lange, , 1998 Greider, 1996 Greider, , 1998 Harley et al., 1995; Kim et al., 1994; Sedivy, 1998; Shay and Bacchetti, 1997; Zakian, 1995) . Although little is known of how telomerase is regulated in telomerase-positive cells, activation is thought to be involved in cellular replicative lifespan extension and cancer cell immortalization (Bodnar et al., 1998; Counter et al., 1998; Kondo et al., 1998; Meyerson et al., 1997; Nakamura et al., 1997; Nakayama et al., 1998; Vaziri and Benchimol, 1998) . Telomerase is a ribonucleoprotein complex containing an RNA subunit and several protein components. The RNA subunit contains the template for telomeric DNA addition and is essential for telomerase activity (Blasco et al., 1996; Broccoli et al., 1996; Feng et al., 1995; Greider and Blackburn, 1989; Kondo et al., 1998; Lee et al., 1998; Niida et al., 1998; Shippen-Lentz and Blackburn, 1990; Tsao et al., 1998) . The protein subunits of telomerase include telomerase reverse transcriptase (TERT) and telomerase associated protein 1 (TEP1). TERT is the catalytic subunit of telomerase Harrington et al., 1997b; Kilian et al., 1997; Lingner and Cech, 1996; Lingner et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997; Nakayama et al., 1998) , whereas TEP1 has been shown to co-purify with telomerase activity and bind to both telomerase RNA and TERT (Harrington et al., 1997a,b; Nakayama et al., 1997) .
Of the telomerase subunits, TERT is concomitantly expressed with the activation of telomerase during cellular immortalization and tumor progression (Harrington et al., 1997b; Kilian et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997; Nakayama et al., 1998) . Introduction of TERT into telomerase negative cells leads to expression of telomerase activity (Bodnar et al., 1998; Counter et al., 1998; Nakayama et al., 1998; Vaziri and Benchimol, 1998; Wen et al., 1998) , elongate telomeres (Bodnar et al., 1998; Vaziri and Benchimol, 1998) , and extend cellular lifespans (Bodnar et al., 1998; Counter et al., 1998; Vaziri and Benchimol, 1998) . In vitro reconstitution of telomerase also shows that TERT and the telomerase RNA subunit constitute a minimum core structure of telomerase (Beattie et al., 1998; Greenberg et al., 1998; Weinrich et al., 1997) . Moreover, recent studies suggest that proto-oncogene c-myc induces expression of TERT and telomerase activity in both normal human mammary epithelial cells and normal human diploid ®broblasts (Takakura et al., 1999; Wang et al., 1998; Wu et al., 1999) , and that anti-c-myc antisense treatment causes inhibition of telomerase activity in three human leukemic cell lines (Fujimoto and Takahashi, 1997) . Thus, de novo activation of TERT gene expression is a ®rst ratelimiting step in telomerase activation in cancer.
To date, little is known of post-translational mechanisms of telomerase regulation. Recent studies show that alteration of the C-terminal structure of hTERT does not aect telomerase enzymatic activity but impedes the ability of this enzyme to maintain telomeres and induce cell immortalization (Counter et al., 1998; Ouellette et al., 1999) . These data suggest that the catalytic activity of hTERT does not always correlate with telomerase function in cells, and some structures of hTERT other than those required for the catalytic activity are also essential for telomerase function in vivo probably through interactions with other molecules. Identi®cations of telomerase interacting proteins and roles of other protein components of telomerase complex such as hTEP1 (Harrington et al., 1997a; Nakayama et al., 1997) and Tetrahymena p95 (Collins et al., 1995) in the regulation of telomerase activity are therefore of importance in our understandings of the control mechanisms of telomerase activity in human cancer.
Studies in our laboratory have shown that activation of telomerase requires phosphorylation of telomerase protein subunits. Both TERT and TEP1 are phosphoproteins in human breast cancer cells, and telomerase exists in two con®gurations with TERT and TEP1 being phosphorylated/dephosphorylated (Li et al., 1997 (Li et al., , 1998 . Phosphorylation is associated with high telomerase activity, and dephosphorylation with low. Protein phosphatase 2A and protein kinase Ca have been shown to be the phosphatase and kinase involved in regulating telomerase activity in human breast cancer cells (Li et al., 1997 (Li et al., , 1998 . To further delineate the post-translational mechanisms of telomerase regulation, the present study was undertaken to characterize the potential role of the tumor suppressor protein p53 in the regulation of telomerase activity. We show by anity chromatography and immunoprecipitation that p53 binds to TEP1 and inhibits telomerase activity. This inhibition requires an intact C-terminal region of the tumor suppressor, and can in turn be blocked by a synthetic peptide derived from a region near the N-terminus of TEP1. Thus, p53 and telomerase may interact directly in the regulation of cell survival.
Results
To identify potential telomerase regulatory proteins, we set up anity chromatography columns with synthetic peptides derived from the sequences of human telomerase-associated protein 1 (hTEP1) and of human telomerase reverse transcriptase (hTERT). These peptides were selected on the basis of prediction of sequence hydrophilicity and charge characteristics. Elution of nuclear proteins from human breast cancer (PMC42) cells in three hTEP1 peptide anity columns showed p53 tumor suppressor protein reactivity. As shown in Figure 1a , p53 from nuclear protein lysates bound selectively to an anity column coupled with hTEP1 peptide (Trp943-Cys959); the tumor suppressor protein Rb did not bind to the column (not shown). The binding appeared to be of high anity with dissociation requiring high concentrations of salt or low pH. Nuclear p53 also bound to anity columns coupled with the hTEP1 peptide (His385-Gly399) or hTEP1 peptide (Asp2538-Arg2551), but not to columns coupled with scrambled peptides or three peptides from human telomerase reverse transcriptase (hTERT) (data not shown). Given that all of the three peptides have previously been suggested to be able to enrich hTEP1 and telomerase activity, these data suggest speci®c complex interactions possibly involving hTEP1 oligomers (Li et al., 1998) . To further explore the speci®city of the interaction between p53 and the hTEP1 peptide anity column, nuclear protein lysates were mixed with the peptide hTEP1 943-959 before loading onto the same peptide anity column. In the presence of excess hTEP1 peptide, binding of p53 to the column was inhibited, with much lesser amounts eluting in the low pH glycine buer (Figure 1b) .
To determine whether or not p53 directly interacts with hTEP1, either puri®ed GST or GST-p53 fusion proteins were loaded onto the peptide anity column coupled with the peptide hTEP1 [943] [944] [945] [946] [947] [948] [949] [950] [951] [952] [953] [954] [955] [956] [957] [958] [959] , followed by sequential elution with high salt and low pH buer. As shown in Figure 1c , GST did not bind to the column, whereas GST-p53 bound to the column and was eluted by low pH glycine buer (Figure 1d , indicated by arrow). The low molecular weight band associated with GST-p53 in lanes P and 18 ± 26 of Figure 1d is likely to be a degraded fragment of GST-p53. When GST-p53 was mixed with soluble hTEP1 [943] [944] [945] [946] [947] [948] [949] [950] [951] [952] [953] [954] [955] [956] [957] [958] [959] peptide and then loaded onto the column in the presence of this peptide, the binding of GST-p53 fusion to the column was markedly inhibited with the fusion protein mainly in the¯ow through and wash fractions (not shown). These data suggest that p53 directly and speci®cally interacts with the hTEP1 peptide.
To determine the potential interaction between p53 and intact hTEP1 protein in human breast cancer cells, proteins were immunoprecipitated from nuclear protein lysates with speci®c antibodies against either p53 or hTEP1. Although hTEP1 could be readily detected by immunoblot analysis of anti-hTEP1 immunoprecipitates (Li et al., 1998) , no hTEP1 was detectable in immunoprecipitates of p53 (data not shown); in contrast, however, signi®cant amounts of p53 (20 ± 35% of total) were found in the immunoprecipitates of hTEP1 ( Figure 1e ). This suggests that only a fraction of p53 was associated with hTEP1, and that those hTEP1 bound p53 molecules were inaccessible to p53 antibody in the immunoprecipitation studies (or were relatively weekly associated with the large telomerase complex). Addition of recombinant wild-type GST-p53 fusion protein into cell lysates before immunoprecipitation also showed co-immunoprecipitation of the fusion protein with hTEP1 ( Figure 1e , lane 6). The association of both endogenous and exogenous p53 proteins with hTEP1 also appeared to be speci®c; addition of the hTEP1 peptide used for antibody generation blocked the immunoprecipitation of hTEP1 (not shown) and thereby co-immunoprecipitation of p53 ( Figure 1e , lanes 5 and 7). The intermediate-sized bands between GST-53 and nuclear p53 in Figure 1e are likely to be degraded GST-p53 fragments. Thus, given that hTEP1 co-immunoprecipitates with hTERT and telomerase activity (Harrington et al., 1997a; Li et al., 1998; Nakayama et al., 1997) , these data demonstrate that a subpopulation of p53 is physically in association with the ribonucleoprotein complex of telomerase, and that association is likely to be mediated at least in part by hTEP1 possibly in cultured human breast cancer PMC42 cells.
Since it is yet to be determined of potential mutations in the amino acid sequence of p53 expressed in the PMC42 breast cancer cells, using three dierent GST-p53 mutants we investigated the potential regions of p53 involved in association with telomerase by immunoprecipitation. While the GST-p53 mutants with a single amino acid residue mutation in the DNA binding domain (R175H) (not shown) or with a truncation in the amino terminus (2C) retained binding activity for telomerase ( Figure 1e , lane 8), the GST-p53 mutant with a deletion of the C-terminus (N5) was less eectively immunoprecipitated relative to nuclear p53 compared with GST-p53 wild-type and GST-p53 mutant (2C) (Figure 1e , lane 10 versus lanes 6 and 8), suggesting an importance of the C-terminal region of p53 in telomerase regulation.
To determine roles for the binding of p53 to telomerase, nuclear telomerase activity was assessed as a function of dierential incubation with dierent recombinant GST-p53 proteins. Incubation with wildtype GST-p53 produced marked inhibition of telomerase activity, with GST itself having no eect ( Figure  2a ). Inhibition occurred immediately after GST-p53 was included (not shown), with an IC 50 for GST-p53 of *40 nM. Since such inhibition might re¯ect nonspeci®c DNA binding of the tumor suppressor, following incubation with telomerase in the presence or absence of GST-p53 de novo synthesized telomere DNA was extracted for speci®c PCR. As shown in Figure 1 Identi®cation of p53 interaction with telomerase hTEP1. (a, b) Binding of p53 from nuclear lysates of human breast cancer cells to a telomerase peptide anity chromatography column. Nuclear protein extracts were loaded onto an Agel-10/15 column coupled with hTEP1 943 ± 959 peptide in the presence (b) or absence (a) of the same hTEP1 peptide, and eluted with a linear KCl gradient and then low pH glycine buer. p53 was detected by immunoblotting. P represents the load onto the column, T thē ow-through fraction and W the wash fraction. (c, d) Elution pro®les for GST and GST-p53 fusion proteins from the telomerase peptide anity chromatography column. Equal amounts (10 mg) of GST (c) or GST-p53 (d) were loaded onto the hTEP1 943 ± 959 peptide anity column and eluted with KCl and glycine buer as above. The proteins eluted from the column were detected by silver staining. (e) Binding of nuclear p53 and GST-p53 to hTEP1 as assessed by immunoprecipitation analysis. Nuclear protein extracts were mixed without (lanes 1 ± 4), or with wild-type GST-p53 (lanes 6 and 7), or GST-p53 with an N-terminal deletion (lanes 8 and 9) or GST-p53 with a C-terminal deletion (lanes 10 and 11) in the presence (lanes 3, 5, 7, 9 and 11) or absence (lanes 1, 2, 4, 6, 8 and 10) of the immunogenic hTEP1 peptide. Samples were immunoprecipitated with normal IgG, anti-p53 or anti-hTEP1 antibodies as indicated. Immunoprecipitated proteins were separated by SDS ± PAGE and examined for p53 immunoreactivity by immunoblotting using anti-p53 antibodies. Co-immunoprecipitated p53 and GST-p53 with hTEP1 are indicated with arrows Figure 2b , telomerase inhibition by GST-p53 was con®rmed not to be due to inhibiting PCR, and thus speci®c. In separate experiments, increasing concentrations of the telomerase substrate (TS) oligonucleotide were added to the telomerase activity incubates in the presence or absence of GST-p53 (Figure 2c ). Under these conditions, inhibition of telomerase by GST-p53 was similarly not aected, suggesting that the inhibition of telomerase by p53 is not mediated by an interaction of p53 with TS oligonucleotide.
To explore the structure-function relationships of GST-p53 in regulating telomerase activity, dierent GST-p53 mutants were tested in the telomerase activity assay. Consistent with the data shown in Figure 2b ,c, a single amino acid mutation in the DNA binding domain (R175H) did not alter the inhibitory eect of p53. N-terminal truncation only slightly attenuated the inhibitory eect of p53 compared with wild-type, whereas deletion of the Cterminal region (Figure 2d ) or both C-and Nterminal regions (not shown) abrogated the inhibitory eect of GST-p53. This is consistent with the ®nding from the immunoprecipitation studies that the Cterminal region is probably involved in telomerase association, and adds weight to the possibility that the interaction mediated through the C-terminal region of p53 is important in p53 regulation of telomerase activity.
Since only a small amount of endogenous p53 coimmunoprecipitates with hTEP1, and added extra amounts of GST-p53 are able to co-immunoprecipitate with hTEP1 and inhibit telomerase activity, we hypothesized that phosphorylation of endogenous p53 might regulate its interaction with telomerase. To test this hypothesis, wild-type GST-p53 was stoichiometrically phosphorylated on glutathione sepharose 4B beads in the presence of [g-32 P]ATP by puri®ed cdc2 protein kinase, protein kinase Ca and casein kinase II, respectively. These protein kinases have previously been shown to phosphorylate p53 in the C-terminal region (reviewed by Ko and Prives, 1996) . When phosphorylation reached to plateaus, the dierentially phosphorylated GST-p53 proteins were extensively washed and eluted, and their eects on telomerase activity tested. Neither cdc2, protein kinase Ca ( Figure  2e ) nor casein kinase II (not shown) aected the inhibitory activity of GST-p53 on telomerase, suggesting that phosphorylation of p53 by these protein kinases plays little role in p53 inhibition of telomerase activity in vitro.
Alternatively, the inhibition of telomerase activity by GST-p53 could re¯ect modulation of telomerase tertiary/quaternary structures aecting intramolecular allosteric reactions. We therefore tested several synthetic peptides derived from hTEP1 and hTERT for their potential eects on both basal and p53-inhibited telomerase activities from nuclei of human breast cancer cells. While none of the three peptides from hTERT, nor the two hTEP1 943-959 and hTEP1
2538-2551 peptides used for anity chromatography had any eect (not shown), the peptide hTEP1 385-399 clearly interacted with telomerase and GST-p53 (Figure 3 ). This peptide, termed telomerase inhibitory polypeptide 1 (TEIPP1), was capable of inhibiting telomerase activity in a concentration-dependent manner, and scrambling TEIPP1 markedly lowered its inhibitory activity (Figure 3a) . In addition, co-incubation of TEIPP1 at varying concentrations with telomerase extracts and GST-p53 showed that TEIPP1 titrated p53 away from the telomerase complex, resulting in a Figure 2 Inhibition of telomerase activity by GST-p53. (a) Concentration-dependent inhibition of telomerase activity by recombinant p53. Puri®ed GST-p53 or GST proteins were included in incubations for assessment of nuclear telomerase activity using TRAP assays (Kim et al., 1994) . An RNase-A control is included as a speci®city control. Results are representative of four separate experiments. (b) The inhibition of telomerase activity by p53 is not an artifact of p53 inhibition of PCR ampli®cation. After incubation of telomerase extracts with p53, de novo synthesized telomeres were phenol/chloroform extracted to remove all proteins and then subjected to telomere-speci®c PCR. RNase-A and heat-treated controls (to deactivate telomerase) were included and the telomerase activity was determined in duplicate. (c) Eects of telomerase substrate (TS) oligonucleotide primer on basal and GSTp53-inhibited telomerase activity in the nuclear lysates of human breast cancer cells. Varying concentrations of TS primer were included in the incubations of telomerase extracts with or without GST-p53 as indicated, which was then subjected to telomerespeci®c PCR. (d) Eects of dierent GST-p53 mutants on telomerase activity. Recombinant GST-p53 fusion proteins were individually included at three dierent concentrations in the TRAP assay with nuclear telomerase extracts from human breast cancer cells. In contrast to the N-terminal deletions (2C, 3C) and DNA-binding domain mutation (R175H), deletion of the Cterminal region (N5) abolished the inhibitory eect of p53 on telomerase. (e) Eects of dierentially phosphorylated GST-p53 on telomerase activity. Wild-type GST-p53 bound to glutathione sepharose 4B beads was incubated with or without puri®ed cdc2 protein kinase or protein kinase Ca under appropriate phosphorylation conditions separately for 20 min at 328C. Following washing to remove the protein kinases and other reagents, dierentially phosphorylated and control GST-p53 were eluted and tested in TRAP assays. Dierent concentrations of the proteins were used and an RNase-A control for telomerase speci®city was included as indicated restoration of telomerase activity at ®xed concentrations of TEIPP1 (Figure 3b,c) . Near complete restoration of p53 inhibition was seen at *1 mM TEIPP1; at higher concentrations of TEIPP1, however, the peptide itself showed inhibitory eects on telomerase activity (Figure 3b ). 
Discussion
The p53 tumor suppressor protein is activated by DNA damage; activation then arrests chromosome replication allowing DNA repair (for reviews, see Levine, 1997; Oren, 1998) . Inactivation of p53 through speci®c interactions with oncogenic proteins, dephosphorylation or genetic mutations (Levine, 1997; Oren, 1998) is involved in cancer cell immortalization (Atadja et al., 1995; Bond et al., 1994; Rogan et al., 1995; Roos et al., 1998; Serrano et al., 1997; Wynford-Thomas, 1996) . Similarly, activation of telomerase also plays an important role in tumor cell immortalization via preventing telomeres from shortening (Bodnar et al., 1998; de Lange, 1998; Greider, 1998; Harley et al., 1995; Kondo et al., 1998; Sedivy, 1998; Shay and Bacchetti, 1997) , although there are scant data on the regulation of telomerase at molecular levels. The present study using anity isolation and recombinant proteins suggests for the ®rst time a possibly direct link between p53 and telomerase and a potential pathway whereby p53 and telomerase interact in the regulation of cellular senescence.
Our results show clearly that both nuclear p53 of human breast cancer cells and recombinant wild-type p53 interact directly with hTEP1 and thus presumably the telomerase complex in vitro. The binding of p53 to the anity chromatography columns coupled with three dierent hTEP1 peptides suggests that p53 interacts with the telomerase complex during chromatography, as both immunoreactive hTEP1 and telomerase activity have been speci®cally eluted from the columns (Li et al., 1998) . This interpretation is also supported by the ®ndings that p53 (Figure 1e ) and telomerase activity (Harrington et al., 1997a; Li et al., 1998) co-immunoprecipitate with hTEP1, and that higher amounts of recombinant p53 speci®cally inhibit telomerase activity in vitro (Figure 2 ). The speci®city of p53 inhibition of telomerase activity was demonstrated by excluding potential non-speci®c interactions with PCR reagents (Figure 2b ) and telomerase substrate oligonucleotide primer (Figure 2c ). Thus, it is possible that a fraction of nuclear p53 may interact with the telomerase complex and thus play an inhibitory role in the regulation of telomerase activity in human breast cancer cells.
Structure-function analysis reveals that the Cterminal region of p53 is important in regulating telomerase activity. Since this region has been shown to be able to bind RNA and to be phosphorylated by cdc2 protein kinase, protein kinase Ca and casein kinase II (Ko and Prives, 1996) , it is possible that p53 regulation of telomerase activity might be mediated by interacting with the telomerase RNA moiety and regulated by protein phosphorylation. However, in vitro phosphorylation of recombinant p53 by either cdc2 protein kinase, protein kinase Ca or casein kinase II elicited no change in p53 inhibition of telomerase, suggesting that p53 phosphorylation by the protein kinases tested plays no role in the p53 regulation of telomerase activity, although our data do not exclude the possibility that other sites are involved. Further study is also required to determine if p53 might interact directly with the telomerase RNA subunit.
In exploring the possible mechanism of p53 inhibition of telomerase activity through interacting with hTEP1, however, we have shown that while the hTEP1 943-959 and hTEP1 2538-2551 peptides have no eect on either basal or p53 inhibited telomerase activity, the peptide hTEP1 385 ± 399 reverses p53 inhibition of telomerase at low dose and inhibits telomerase activity itself at high dose (Figure 3b,c) . The peptide hTEP1 385-399 may thus prove very useful in the study of telomerase structure and function, and for convenience we have called it telomerase inhibitory polypeptide 1 or TEIPP1. These data are consistent with an intimate, possibly direct involvement of a sequence including hTEP1 [385] [386] [387] [388] [389] [390] [391] [392] [393] [394] [395] [396] [397] [398] [399] , or TEIPP1 itself, in mediating p53 inhibition of telomerase activity. In addition, the inhibitory eect of TEIPP1 on p53 inhibition of telomerase provides further evidence that the inhibition of telomerase activity by p53 is not non-speci®c, Figure 4 A cartoon illustrating the mechanisms postulated to underlie the interactions between telomerase, p53 and TEIPP1. Telomerase (globule shaped) may maintain its activity with the Nterminal region of hTEP1 being involved in forming and/or maintaining a potentially active con®guration. Added p53 (pentagon) may interact with this region resulting in a conformational change and low telomerase activity. Added TEIPP1, corresponding to this N-terminal region of hTEP1, may competitively inhibit the natural folding of hTEP1 leading to lowered activity similar to that induced by p53. When both p53 and TEIPP1 are added together, inhibition by either can be prevented at appropriate concentrations or return at higher concentrations of either p53 or TEIPP1 but rather a speci®c protein interaction with hTEP1. Furthermore, the eects of TEIPP1 on both telomerase and p53 activities also con®rms a regulatory role of hTEP1 in telomerase activity, and provide a novel insight into the inter-and intramolecular control mechanisms of telomerase.
Given that hTEP1 is associated with telomerase activity (Li et al., 1998) and p53 (Figure 1) and that additional TEIPP1, the sequence near the N-terminus of hTEP1 antagonizes the inhibition of telomerase activity by exogenously added p53, it is possible that hTEP1, TERT, telomerase RNA, and p53 form a complex and in the presence of excess amounts of TEIPP1 or p53 telomerase activity is then inhibited, although the possibility cannot be excluded of mutually exclusive binding of hTEP1 to p53 or TERT. As depicted in Figure 4 , TEIPP1 may play an essential role in forming and maintaining an active telomerase con®guration through interacting with another region of the telomerase complex. p53 may interact with this sequence to disrupt telomerase activity, whereas additional TEIPP1 may competitively bind elsewhere, perhaps to inhibit the correct folding of telomerase and leading to inhibition of telomerase activity in a manner similar to that seen with p53 ( Figure 4 ). When p53, TEIPP1 and telomerase are all together, TEIPP1 may competitively bind to the tumor suppressor to block its inhibition on telomerase, and at higher concentrations inhibit telomerase activity by interacting with dierent regions of the telomerase complex (Figure 4) .
Taken together, the data that p53 binds to and inhibits telomerase in vitro argue strongly in favor of the possibility that p53 is an important regulatory factor modulating activity of telomerase in the nucleus of human breast cancer cells. It is possible that among potentially multiple factors, p53 modulates telomerase activity post-translationally through interacting with hTEP1 following TERT and telomerase RNA expression and holoenzyme assembly. Previous studies have shown that human papillomavirus type 16 E6 protein that targets p53 for degradation activates telomerase in a p53-independent manner in early precrisis passage human keratinocytes and mammary epithelial cells (Klingelhutz et al., 1996) . In addition, occasional normal human mammary epithelial cells transfected with a p53 mutant become immortalized and upon additional genetic events reactivated for telomerase (Gollahon and Shay, 1996) . These studies support the idea that p53 loss of function alone is inecient in activating telomerase and other factors are also involved in telomerase activity. Given that p53 function is lost in *50% (Levine, 1997; Oren, 1998) and telomerase activated in *85% (Kim et al., 1994; Shay and Bacchetti, 1997) of human cancers, and the direct in vitro interactions between telomerase and p53, whether or not down-regulation of p53 may be frequently involved in up-regulating telomerase activity in vivo during cancer development requires further investigation. Identi®cation of the peptide sequences of p53 and hTEP1 involved in their mutual interaction and with TEIPP1 in telomerase inhibition may provide both a testable system for investigating molecular interactions and the tertiary structures of telomerase proteins, and a potential therapeutic avenue for altering telomerase activity in anti-cancer therapy.
Materials and methods

Cells, peptides and anity chromatography
The human mammary carcinoma cell line, PMC42, was grown in vitro in a hormone-dependent manner (Whitehead et al., 1984) and lyzed for nuclear extracts before anity chromatography (Li et al., 1997) . Several peptides corresponding to regions of human TEP1 (hTEP1) and human TERT (hTERT) were synthesized and puri®ed to 470% purity by Chiron Technologies Pty. Ltd. (Victoria, Australia). The peptides were coupled onto Agel-10/15 beads as described elsewhere (Li et al., 1998) . Approximately 10 mg protein of nuclear extract from human breast cancer PMC42 cells, or 10 mg puri®ed protein, were loaded onto the column coupled (bed volume, 10 ml) at ā ow rate of *0.5 ml/min. Following extensive washing (56bed volumes), proteins were eluted from the column with KCl (0 ± 300 mM) and then glycine buer (0.1 mM, pH 2.4). The collected fractions were subject to SDS ± PAGE followed by Coomassie blue staining or immunoblotting using speci®c antibodies. Alternatively, in some experiments nuclear extracts or puri®ed GST-fusion protein was mixed with synthetic peptide before loading the sample onto the anity column coupled with the same peptide.
Antibodies, immunoprecipitation and immunoblotting
Anti-hTEP1 antibody was produced by immunizing rabbits with the hTEP1 peptide 2538 DSEPTPHLKTRQRR 2551 coupled to BSA and then anity-puri®ed on the same peptidecoupled column (Li et al., 1998) . The antibody has been shown to be speci®c in immunoblotting, immunoprecipitation (Li et al., 1998) and immunocytochemical studies (unpublished). Anti-p53 and anti-Rb antibodies were from Santa Cruz Biotechnology, Inc., CA, USA. The anti-p53 antibody (DO-1) was covalently coupled to agarose for immunoprecipitation, and the anti-p53 antibody to the central DNA binding domain (Pab240) was used for immunoblotting. To determine interactions between hTEP1 and endogenous as well as exogenous p53, equal amounts of nuclear proteins (100 mg) plus or minus dierent GST-p53 fusion proteins (1 mg) in the presence or absence of the immunogenic hTEP1 peptide were subjected to immunoprecipitation with either normal IgG as a control, anti-p53 antibodies, or anti-hTEP1 antibody. Proteins in the immunoprecipitates were separated by SDS ± PAGE, transferred onto nitrocellulose membranes, and probed with either anti-hTEP1, anti-p53 or anti-Rb antibodies, followed by ECL detection (Amersham) and autoradiography.
Recombinant GST-fusions, protein phosphorylation and puri®cation
Wild-type and various mutants of GST-p53 were produced as described previously (Ruppert and Stillman, 1993) . Brie¯y, for wild-type and the mutants with deletion of the N-terminal regions (2C: 95 ± 393 and 3C: 155 ± 393) or a single DNAbinding domain mutation (R175H), pET11GTK plasmids containing relevant p53 cDNAs (kindly provided by Dr Bruce Stillman) were ampli®ed and puri®ed. For the Cterminal deletion (N5: 2 ± 293), a DNA fragment was generated by speci®c PCR using a wild-type human p53 cDNA in pC53-SN 3 plasmid as template and the synthetic oligonucleotides (gcaggtaccggaggagccgcag (jp33) and taggatccccctttcttgcgg (jp36)) as primers. It was then subcloned into the pET11GTK plasmid and the recombinant plasmid DNA was ampli®ed and then puri®ed. For double N-and Cterminal deletions, the GST-p53 mutant cDNA was constructed by subcloning a PCR cDNA fragment into the pET11GTK plasmid with the synthetic oligonucleotides (gctggtaccgtcttctgtccct (jp35)) and jp36 as primers. The recombinant plasmid DNA was then ampli®ed and puri®ed as above. After sequence veri®cation, the cloned plasmids were individually transformed into E. coli BL21 (DE3) to produce the fusion proteins under IPTG induction. Recombinant GST-p53 fusion proteins were puri®ed and identi®ed by SDS ± PAGE as described elsewhere (Ruppert and Stillman, 1993) . For phosphorylation of the recombinant proteins, GST and GST fusions on glutathione sepharose 4B beads were incubated with puri®ed cdc2 protein kinase, protein kinase Ca and casein kinase II separately in phosphorylation buer containing ATP (*40 mM, 3 mCi [g- (1 mM) and other kinase speci®c activators, and the reaction allowed to proceed at 308C for *20 min followed by extensive washing of beads with 0.5 M NaCl and cold PBS. All recombinant GST fusions were eluted from the beads in reduced glutathione buer and examined for their actions with reduced glutathione solution as control. Puri®ed cdc2 protein kinase was from Upstate Biotechnology, Inc. (New York, NY, USA), protein kinase Ca was from Biomol Research Laboratories (Plymouth Meeting, PA, USA) and casein kinase II from Promega Corporation (Madison, WI, USA).
Telomerase activity assay
A TRAP assay, performed essentially as described previously (Kim et al., 1994) , was employed to determine eects of p53 on telomerase activity. Brie¯y, equal amounts of nuclear telomerase extracts (1 mg) were incubated in the presence or absence of recombinant proteins or/and synthetic peptides as indicated in particular experiments. Following incubation, de novo synthesized telomeres were ampli®ed by speci®c PCR and the resultant 32 P-labeled telomeres resolved by polyacrylamide slab gel electrophoresis followed by autoradiography. To exclude any potential eect of proteins on PCR, de novo synthesized telomeres were extracted with phenol and chloroform post-incubation with telomerase and the isolated telomeres used in PCR ampli®cation. To verify the speci®city of telomerase, negative controls consisting either of added RNase-A or sample heated to 808C to inactivate telomerase were included in each telomerase activity assay. To establish the speci®city of actions of GST-p53 proteins and synthetic peptides, GST alone, relevant mutated proteins and scrambled peptides were compared as indicated in individual experiments.
